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Abstract
The low molecular weight compound, PRIMA-1MET restores the transcriptional transactivation
function of certain p53 mutants in tumor cells. We have previously shown that PRIMA-1MET induces
nucleolar translocation of p53, PML, CBP and Hsp70. The Epstein-Barr virus encoded, latency
associated antigen EBNA-5 (also known as EBNA-LP) is required for the efficient transformation
of human B lymphocytes by EBV. EBNA-5 associates with p53-hMDM2-p14ARF complexes. EBNA-
5 is a nuclear protein that translocates to the nucleolus upon heat shock or inhibition of
proteasomes along with p53, hMDM2, Hsp70, PML and proteasome subunits. Here we show that
PRIMA-1MET induces the nucleolar translocation of EBNA-5 in EBV transformed B lymphoblasts and
in transfected tumor cells. The PRIMA-1MET induced translocation of EBNA-5 is not dependent on
the presence of mutant p53. It also occurs in p53 null cells or in cells that express wild type p53.
Both the native and the EGFP or DSRed conjugated EBNA-5 respond to PRIMA-1MET treatment in
the same way. Image analysis of DSRed-EBNA-5 expressing cells, using confocal fluorescence time-
lapse microscopy showed that the nucleolar translocation requires several hours to complete.
FRAP (fluorescence recovery after photobleaching) and FLIP (fluorescence loss in photobleaching)
measurements on live cells showed that the nucleolar translocation was accompanied by the
formation of EBNA-5 aggregates. The process is reversible since the aggregates are dissolved upon
removal of PRIMA-1MET. Our results suggest that mutant p53 is not the sole target of PRIMA-1MET.
We propose that PRIMA-1MET  may reversibly inhibit cellular chaperons that prevent the
aggregation of misfolded proteins, and that EBNA-5 may serve as a surrogate drug target for
elucidating the precise molecular action of PRIMA-1MET.
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Introduction
Epstein-Barr virus (EBV) is the most powerful transform-
ing agent of human cells. EBV infected resting B cells
undergo blast transformation and develop into immortal
lymphoblastoid cell lines (LCLs) in vitro or into immuno-
blastic lymphomas in immunocompromised host. Nine
latent viral proteins are expressed regularly in the trans-
formed cells: the nuclear antigens, EBNA1–6, and three
membrane proteins, LMP-1, -2a and -2b. Six of these pro-
teins are required for immortalization: EBNA-1, -2, -3
(3A), -5 (LP), -6 (3C) and LMP-1 [1,2]
EBNA-5 and EBNA-2 are the first two viral proteins
expressed in newly infected cells [3]. The co-expression of
EBNA-2 and EBNA-5 plays an important role already at
the first steps of EBV induced transformation by driving
resting B cells into the cell cycle [4]. The co-operation
between EBNA-2 and EBNA-5 is needed for the activation
of LMP-1 and Cp viral promoters [5].
EBNA-5 preferentially accumulates in distinct nuclear foci
in EBV-transformed lymphoblastoid cell lines. We have
previously shown that these foci are inside the PML bod-
ies [6]. We have also shown that the same foci contained
the retinoblastoma (Rb) protein and the heat shock pro-
tein, Hsp70 [7]. Artificial spreading of the chromatin by
exposure to the forces of fluid surface tension disrupted
the co-localization gradually. It showed that EBNA-5 is
located in the inner core of the bodies whereas PML
formed the rigid outer shell [6].
Nuclear bodies with prominent PML staining are seen in
uninfected resting B lymphocytes. This staining pattern
does not change upon EBV infection. In freshly infected
cells EBNA-5 is diffusely distributed throughout the
nucleoplasm but after a few days gradually relocate to the
PML bodies and remains there in established lymphoblas-
toid cell lines [8]. The localization of EBNA-5 to PML bod-
ies is restricted to EBV- infected human lymphoblasts.
Exogenously expressed EBNA-5 in any other cell lines dis-
tributes homogeneously in the nucleoplasm [9].
Heat shock or high cell density induced metabolic stress
leads to the translocation of EBNA-5 to the nucleoli both
from the PML bodies or from the nucleoplasm [10]. Sub-
sequently we found that proteasome inhibitors induced
also nucleolar translocation of EBNA-5 in both LCLs and
transfected cell lines. They also induced nucleolar translo-
cation of Hsp70 protein and mutant p53. Translocation of
the later was enhanced by the presence of EBNA-5 [9]. In
a separate study, we have shown that proteasome inhibi-
tors can induce nucleolar translocation of various compo-
nents of the PML body and nuclear/nucleolar
accumulation of proteasomes [11].
The precise role of EBNA-5 in the virus induced transfor-
mation has nor yet been established. It binds to p14ARF-
hMDM2-p53 complexes. Forced overexpression of
p14ARF leads to the formation of extranucleolar inclu-
sions with subsequent entrapment of hMDM2, p53 and
EBNA-5 [6,12-14].
PRIMA-1 has been identified through differential screen-
ing of the structural diversity set of the NCI chemical
library, as a drug that selectively induces apoptosis in
mutant p53 bearing human tumor cells but not in their
p53 -/- counterparts [15]. Treatment with PRIMA-1 sup-
presses the growth of mutant p53 expressing human
tumor xenografts in vivo [16,17]. PRIMA-1 can restore the
transcriptional transactivating function of certain p53
mutants and induce p53 dependent apoptosis [15].
Recently, we have shown that PRIMA-1MET, a methylated
derivative of the original PRIMA with improved pro-apop-
totic activity, causes nucleolar translocation of mutant
p53 and of PML, CBP and Hsp70. The level of Hsp70 was
significantly increased by PRIMA-1MET  treatment. The
nucleolar accumulation of PML, CBP and Hsp70 was
much more efficient in cells with mutant p53 as com-
pared to p53-/- cells [18]. PRIMA-Dead, a compound
structurally related to PRIMA-1MET but unable to induce
mutant p53-dependent apoptosis, failed to induce nucle-
olar translocation of mutant p53. These results suggested
that redistribution of mutant p53 to nucleoli plays a role
in PRIMA-1MET induced apoptosis.
Considering the intimate relationship between EBNA-5
and the p53 pathway as well as the obvious similarities
between the proteasome inhibitor and PRIMA-1MET
induced nucleolar translocation of p53, PML and Hsp70,
we have now investigated the effect of PRIMA-1MET on the
subcellular distribution of EBNA-5. Here we show that
PRIMA-1MET induces the nucleolar translocation of both
virus encoded endogenous and transfected exogenous
EBNA5 and its fluorescent derivatives GFP-EBNA5 and
DSRed-EBNA-5.
Methods
Cell cultures
All cell lines were grown in Iscove's cell culture medium
supplemented with 10% heat-inactivated FBS, 2 mM L-
glutamine, 100 U/ml penicillin and 100 U/ml streptomy-
cin. The cells were passaged every fourth day 1:5. Cultures
were regularly tested for the absence of mycoplasma with
Hoechst 33258 staining. Transfections were done using
Lipofectamine Plus reagent (GibcoBRL) according to the
manufacturer's instructions. In the present study the fol-
lowing cell lines were used: LSsp, EBV transformed lym-
phoblastoid B-cell line, H1299 lung adeno carcinoma line
(p53 -/-) and its mutant p53 transfected subline (with HisMolecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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175), SW480, a colorectal cancer line with mutant p53
(Arg to His 273 and Pro to Ser 309). MCF-7, a breast car-
cinoma line bearing wild-type p53. Clones of MCF-7 and
SW480 lines (S2 carrying EBNA-5 and P2 vector control),
constitutively expressing EBNA-5 from a pBabe-EBNA-5
construct were generated using selection with 1 μg/ml
puromycin (Sigma). MCF7 cells constitutively expressing
DsRed_EBNA-5 were selected on 1 mg/ml G418 (Sigma).
Constructs
GFP-EBNA-5 was made by cloning an EBNA-5-encoding
BamHI-EcoRI fragment from pBabe-EBNA-5, containing
four W repeats and the unique C-terminal region, into
BglII-EcoRI-cleaved pEGFP-N1 [13]. To produce red fusion
protein EBNA-5 was amplified with primers containing
NheI-EcoRI 5'overhangs. The cleaved PCR product was
cloned into the corresponding sites of pDsRed1-N1 vector
(Clontech).
PRIMA-1MET-treatment and immunofluorescence staining
The monoclonal mouse antibody JF186 was used against
EBNA-5 [19] and the MAb used against B23/nucleophos-
min was a gift from P. K. Chan, Baylor College of Medi-
cine, Houston, USA. The cells were cultured on cover slips
in six-well plates until they have reached a density of 5 ×
104 cells/cm2 and incubated for 24 h in the presence of 50
μM PRIMA-1MET  dissolved in dimethylsulphoxide
(DMSO). Cells treated with DMSO were used as controls.
Cells were fixed with methanol-acetone (1:1) at -20°C
and then were re-hydrated in phosphate-buffered saline
(PBS) for 30 min. Antibodies were diluted in blocking
buffer (2% bovine serum albumin, 0.2% Tween-20, 10%
glycerol in PBS). The cells were stained with primary
MAbs for 1 h at room temperature, followed by three
washes in PBS, incubated with secondary FITC or Texas
red-conjugated antibodies, washed three times and
mounted with 80% glycerol solution in PBS containing
2·5% 1,4-diazabicyclo-(2.2.2)octane (Sigma). Bisbenz-
imide (Hoechst 33258) was added at a concentration of
0·4 μg/ml to the secondary antibody for DNA staining.
Live cell microscopy
Long term live cell fluorescence imaging was carried out in
POC Mini chambers. The DSRed-EBNA-5 expressing cells
were grown on the round cover glass insert of the POC
Mini chamber (Carl Zeiss), The chambers were loaded
with 400 ul cell culture medium and were used in fully
closed mode. The imaging was carried out on an
Ultraview LCI three line laser Nipkow spinning disc con-
focal microscope system with a CSU10 Yokogawa head
(Perkin Elmer) assembled on a Zeiss Axiovert motorized
microscope. During the imaging the temperature was
maintained at 37 C with the help of heat controller block
covered with a transparent plexi shield. The heat loss,
toward the oil immersion objective, was prevented by the
use of a separate objective heather ring. Both the control-
ler block and the heater ring were controlled by a com-
mon electric thermostate. The four dimensional image
capture was carried out using the custom developed soft-
ware "FiveColorMovie" written by us, using the Openlab
Automator visual programming environment (Improvi-
sion). To ensure the maintenance of proper focal plane
during the extended imaging periods we have developed
an autofocusing program module that uses recursive min-
imum/maximum intensity measurements at 100 separate
small squares of a matrix overlayed on the gaussian
blurred cental region of interest (ROI) of the raw image.
To find the focus, series of short (50 microsecond) expo-
sitions are made at different Z axis positions that are clus-
tered around the last used focal plane, and extended in
height that is twice the length of the imaging stack. The
section with the greatest difference between the minimum
and maximum intensity values is selected as sharpest. The
Z position of the sharpest image then serves as the central
point for the consequent capturing of 10 images arranged
in a Z stack with exposition times in the range of 500 to
1000 milliseconds. To conveniently capture several hun-
dreds of multicolour images along the time axis the indi-
vidual Z stacks were collapsed "on-the-fly" using
maximum intensity projection algorithm. By saving the
images after every 200 time points the program assures
that the image capture process is not limited by the RAM
but by the available hard disc space.
Photokinetic measurements of recombinant EBNA-5 in live 
cells
To measure the intracellular mobility of EBNA-5 in differ-
ent intranuclear compartments of treated and control cells
we used an Ultraview RS five line laser Nipkow spinning
disc confocal system with a CSU22 Yokogawa head (Per-
kin Elmer) assembled on a Nikon inverted fluorescence
microscope. To achieve pixel precise bleaching of selected
areas a galvanometric Photokinesis unit (Perkin Elmer)
with separate laser input was installed between the
Ultraview unit and the photoport of the microscope. The
timelapse 4D imaging with single (FRAP) and repeated
(FLIP) bleach cycles was carried out with the Ultraview
capture software (Perkin Elmer). The captured images
were quantified using the analytic routines of the
Ultraview program as well as the program ImageJ (Ras-
band, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/). For
FRAP and FLIP studies DSRed-EBNA-5 expressing cells
were grown on the bottom glass of a POC Mini chamber.
The selected areas were bleached using the 568 nm line of
an Argon-Krypton laser. In a typical FRAP recording two
prebleach images were followed by 100 bleach cycles
(total 300–1000 ms) and the recovery was measured by a
series of 500 ms exposition over 1 to 3 minutes (120–360Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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images). In the FLIP experiments the bleach cycles were
followed by the capture of ten images and then the bleach
cycles were repeated several times.
Results
Immunofluorescence staining of EBNA-5 in fixed cells
To study the effect of PRIMA-1MET on the subcellular local-
ization of EBNA-5, EBV transformed lymphoblastoid cell
lines and EBNA-5 transfected tumor cells were treated
with various concentrations of the drug for 24 hours.
Beside native EBNA-5 we have also used EBNA-5 conju-
gated to the C-terminus of the fluorescence protein EGFP
or DSRed. Upon completion of the treatment the cells
were fixed with methanol:aceton and stained with the
monoclonal anti-EBNA-5 antibody JF186.
We found that 12–24 hours treatment with 50 uM
PRIMA-1MET induced nucleolar translocation of EBNA-5
in all cell lines such as the lymphoblastoid cells LSsp
expressing virus encoded endogenous EBNA-5 (Figure 1)
and transfected tumor cell lines such as the colon carci-
noma line SW480 (endogenous mutant p53; Figure 2),
the breast carcinoma line MCF7 (wt p53) and the lung
adeno-carcinoma line H1299 (p53 null cells) as well as its
transfected variant expressing mutant p53 (His175). The
identity of the nucleolus was ascertained by B23 staining
and/or phasecontrast imaging in parallel.
In untreated, transfected cells EBNA-5 localized to the low
DNA density areas corresponding to the euchromatin
(Figure 3). It was either absent from the nucleolus or if
present its level did not exceed the amount in the nucleo-
plasm (Additional file 1 and additional file 2). In the
PRIMA-1MET-induced translocation of virus encoded endog- eneous EBNA-5 in the Epstein-Barr virus transformed human  lymphoblastoid cell line LSsp that carries virus encoded  EBNA-5 and harbors wild type p53 Figure 1
PRIMA-1MET-induced translocation of virus encoded 
endogeneous EBNA-5 in the Epstein-Barr virus 
transformed human lymphoblastoid cell line LSsp 
that carries virus encoded EBNA-5 and harbors wild 
type p53. 24 hours treatment with 50 uM PRIMA-1MET leads 
to the disappearance of EBNA-5 from the PML bodies and to 
relocation to the nucleolus.
PRIMA-1MET-induced translocation of exogenous EBNA-5 in  mutant p53 carrying SW480 colon carcinoma cells after 24  hours treatment Figure 2
PRIMA-1MET-induced translocation of exogenous 
EBNA-5 in mutant p53 carrying SW480 colon carci-
noma cells after 24 hours treatment. Immunofluores-
cence staining of EBNA-5 is green, DNA staining using 
Hoecsht 33258 is blue.
Distribution of DSRed-EBNA-5 in the nucleus of a living  MCF7 cell that carries wild type p53 Figure 3
Distribution of DSRed-EBNA-5 in the nucleus of a liv-
ing MCF7 cell that carries wild type p53. Single confocal 
section selected from the middle of a series of 21 images.Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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treated cells there was an overall increase of EBNA-5 levels
with a very prominent increase in the nucleolus. After 20
hours of treatment almost all diffuse nucleoplasmic
EBNA-5 signal was concentrated in numerous distinct foci
evenly distributed throughout the entire nucleus.
To test the possible influence of EBNA-5 on the survival
rate of PRIMA-1MET treated cells we have compared wild
type and mutant p53 carrying cells stably transfected with
EBNA-5 and their vector controls. PRIMA-1MET treatment
had no effect on the survival rate of wild type p53 carrying
MCF7 breast carcinoma cells with or without EBNA-5 at
any PRIMA-1MET concentrations, although the cells
showed prominent nucleolar translocation of EBNA-5.
Comparing EBNA5 transfected (S2) and vector control
transfected (P2) SW480 colon carcinoma cells that express
mutant P53 we found that the presence of EBNA-5 slightly
sensitized to the PRIMA-1MET effect. (Additional file 3).
Kinetics of nucleolar translocation of DS-redEBNA5 cells 
in PRIMA-1MET treated cells
To study the dynamics of PRIMA-1MET induced nuclear
movements of EBNA-5 we used an automated confocal
microscopy method, developed by us, for live cell imaging
(see Materials and Methods). The technique permits con-
tinuous recording of living cells using a combination of
fluorescence and phase contrast illumination over several
(6–24) hours. We found that the cells tolerated excellently
the combination of 568 nm epifluorescence and 600 nm
transmitted phase contrast illumination. On the other
hand using shorter wavelengths (405 and 488 nm) always
led to visible phototoxic effects during prolonged experi-
ments. Imaging cells stably transfected with DSRed-
EBNA-5 revealed that EBNA-5 that was originally evenly
distributed in the nucleoplasm successively accumulated
in the nucleoli between 6 and 10 hours after the PRIMA-
1MET treatment (Figure 4 and Additional file 4). EBNA-5
accumulation was associated with the formation of 15–20
round or ovoid particles of the size of 250–300 nm that
showed limited movement inside the nucleolus. The
nucleolar accumulation has regularly started from a single
focus in a given nucleolus. Different nucleoli started the
process at different time. Some nucleoli showed up to four
hours delay as compared to the earliest accumulating
nucleoli in the same nucleus. After 10 hours treatment
with PRIMA-1MET  the nucleoli became saturated with
Time lapse series of PRIMA-1MET-induced translocation of DSRed-EBNA-5 in stably transfected MCF7 cells Figure 4
Time lapse series of PRIMA-1MET-induced translocation of DSRed-EBNA-5 in stably transfected MCF7 cells. 
Images at 1 hour interval were selected from a series of 720 images recorded in every minutes for 12 hours.Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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EBNA-5. At this point some of the brightly fluorescent
DSRed-EBNA-5 particles were released from the nucleolus
and moved around in the nucleoplasm by rapid Brownian
movement (Additional file 5). The nucleolar accumula-
tion was also accompanied by an overall increase of
DSRed-EBNA-5 fluorescence intensity (Figure 5).
Effect of PRIMA-1MET on the mobility of DSRed-EBNA-5
We carried out FRAP and FLIP analysis on untreated and
PRIMA-1MET-treated, DSRed-EBNA-5 transfected MCF7
cells to measure the rate of mobility of EBNA-5 in differ-
ent nuclear sub-compartments. In the untreated control
cells the bulk of DSRed-EBNA-5 was homogenously dis-
tributed throughout the nucleoplasm. This fraction
showed very high mobility. Using single bleaching FRAP
with 2 um spot size the average half recovery time (T 1/2)
was 1.5 second that corresponds to a diffusion coefficient
of 0.66 um2/s. In comparison the calculated mobility in
free solution would be 54.6 um2/s.
Imaging the fluorescence loss in the non-illuminated
areas (FLIP) showed a rapid depletion of the homogene-
ous signal from the entire nucleoplasm. The minor popu-
lation of nucleolar DSRed-EBNA-5 in the non-treated cells
showed a higher resistance to FLIP. The nucleolar DSRed-
EBNA-5 was localized to distinct separated areas inside
the nucleolus. Using pixel precise bleaching of the indi-
vidual areas in FRAP experiments we could identify two
levels of recovery one intermediate (T 1/2 21 second) and
one very slow (T 1/2 >> 300 s). The presence of the two
separate nucleolar subcompartment was also confirmed
by FLIP experiments. (Figure 6 and Additional file 6)
Treatment with PRIMA-1MET led to the accumulation of
DSRed-EBNA-5 in well-defined granules in the nucleolus
with very low molecular mobility. In other words,
repeated bleaching of adjacent nucleoplasmic areas, sepa-
rate DSRed-EBNA-5 positive foci in the same nucleolus or
even part of the same granules failed to induce any signif-
icant loss of fluorescence in the non-bleached structures
(Figure 7).
After 20 hours of treatment DSRed-EBNA-5 in addition to
the nucleolar aggregates formed rigid bodies evenly scat-
tered in the nucleoplasm. FLIP showed that these bodies
contained DSRed-EBNA-5 with similar low exchange
mobility as the nucleolar aggregates. These bodies showed
also relatively rapid translational Brownian movement
similarly to the ones released from overfilled nucleoli. An
important distinction however from the former was that
the nucleoplasmic bodies were somewhat larger (400 nm
versus 300 nm) and their movement trajectories were
much more restricted (Figure 7 and Additional file 7).
Whereas the bodies released from the nucleolus could
travel to any area of euchromatin the bodies that were pre-
cipitated out at the later time point in the nucleoplasm
moved within a well-defined sphere of 800–1200 nm.
After 24 hours of treatment the nucleoplasmic bodies
increased in size but not in number (Additional file 8).
Reversibility of PRIMA-1MET induced aggregation of 
DSRed-EBNA-5
PRIMA-1MET regularly induces apoptosis in mutant p53
expressing cells. To explore the possibility whether the
protein aggregation phenomenon is a feature advanced
stage cellular agony we have treated DSRed-EBNA-5
expressing, p53 -/-, H1299 cells with PRIMA-1MET for 12
hours. These cells are much less sensitive to PRIMA-1MET
induced apoptosis than its mutant p53 expressing deriva-
tives. The drug treatment induced nucleolar accumulation
of the protein in most nucleoli. Removing PRIMA-1MET by
repeated washing with drug free medium led to the com-
plete dissolution of the aggregates as it could be demon-
strated by combined fluorescent/phase contrast time lapse
microscopy. No cytopathic effects were detected at any
time during the experiment (Figure 8).
Discussion
The most straightforward explanation of the observed
effects is that PRIMA-1MET induces a gradual precipitation
of EBNA-5. In untreated cells EBNA-5 moves around with
high mobility in the nucleoplasm but slows down in the
nucleolus. We suggest that this is due to the mechanical
sieving effect of the densely arranged chromatin fibers in
the zona fibrillaris of the nucleolus (see Additional file 2
for illustration of the density of chromatin fibers in the
nucleoplasm and in the nucleolus in a living cell nucleus).
In our scenario the drug treatment induces gradual aggre-
PRIMA-1MET treatment leads to an overall increase of DSRed- EBNA-5 levels as shown by plotting the average fluorescence  intensity against time of the 720 frames shown in Figure 4  after background subtraction Figure 5
PRIMA-1MET treatment leads to an overall increase of 
DSRed-EBNA-5 levels as shown by plotting the aver-
age fluorescence intensity against time of the 720 
frames shown in Figure 4 after background subtrac-
tion.Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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Fluorescence loss in photobleaching (FLIP) experiment of untreated DSRed-EBNA-5 expressing MCF7 cells show very high  mobility of homogeneously distributed DSRed-EBNA5 Figure 6
Fluorescence loss in photobleaching (FLIP) experiment of untreated DSRed-EBNA-5 expressing MCF7 cells 
show very high mobility of homogeneously distributed DSRed-EBNA5. Region of interest 1 (ROI 1) was bleached for 
300 ms followed by recording of 10 consecutive images at 500 ms intervals. These cycles were repeated for 5 minutes. ROI 1 
and 5, representing the total bleached area and a selected bleached subarea, showed rapid recovery of fluorescence. ROI 2, 
representing a remote non-bleached area in the nucleoplasm showed rapid homogeneous decrease of fluorescence. ROI 6 in 
adjacent cell showed no changes. ROI 3 and 4 in the nucleolus show two differently equilibrating compartment one faster (ROI 
3) and one slower (ROI 4).Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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20 hours treatment with PRIMA-1MET leads to the loss of mobility of DSRed-EBNA-5 in MCF7 cells as shown by FLIP experi- ment Figure 7
20 hours treatment with PRIMA-1MET leads to the loss of mobility of DSRed-EBNA-5 in MCF7 cells as shown by 
FLIP experiment. ROI 1 was bleached as above but showed no significant recovery. Adjacent ROI 2 and distant ROI 3 
showed no significant loss of fluorescence.Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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gation of EBNA-5 and the aggregates start to clog the
nucleolar chromatin fiber meshwork. Heterogeneity in
the sieving effect ("effective pore size") of different subnu-
cleolar compartments or even between different nucleoli
could explain the phenomena of: a.) focal initiation of
nucleolar accumulation b.) nucleolar subcompartments
with different mobility identified by FLIP c.) asynchro-
nous accumulation of EBNA-5 in different nucleoli.
Along the same lines we also suggest that upon prolonged
(20+ hours) treatment with PRIMA-1MET, the in situ fall-
ing out of EBNA-5 precipitates in the nucleoplasm is due
to the convergence between the size of the precipitated
bodies and the sieving dimensions of the 300 nm chroma-
tin fibre meshwork of the nucleoplasm. This is also con-
sistent with the finding that nucleoplasmic EBNA-5
aggregates show spatially restricted and uniform random
walk trajectories (Additional file 7 and Additional file 8).
Conformational change due to mutation or thermal, acid-
base or redox change that leads to increased surface expo-
sition of otherwise cryptic hydrophobic side chains is the
most usual cause of protein precipitation. Exposed hydro-
phobic surfaces are potent inducers of cellular heat shock
responses. Increased exposition of hydrophobic surfaces
lead to increased expression of molecular chaperons that
actively counteract the precipitation process, by isolating
the misfolded proteins from each other and using the
energy of hydrolyzed ATP for actively "massaging" their
protein client back to a native conformation that repre-
sents the lowest level of folding energy. Importantly
mutant p53 was recently found in complex with Hsp90 in
PRIMA-1MET treated cells [20]. Hsp90 is a major constitu-
ent of the proteome, comprising up to 5% of the total
mass of cellular proteins. It remains to be elucidated to
what extent mutant p53 is associated with other, less
abundant heat shock proteins in the presence and absence
of PRIMA-1MET.
It is well known however that mutant p53 often com-
plexes with Hsp70 [21]. Association of Hsp70 and CHIP
(carboxy terminus of Hsp70-interacting protein) is
responsible for ubiquitination and degradation of some
of the p53 mutants [22]. Our present findings suggest that
PRIMA-1MET might act through reversible inhibition of
cellular chaperon activity. In this scenario the aggregation
of EBNA-5 (or mutant p53) would be prevented by the
constitutive activity of Hsp70 type cellular chaperons.
Inhibition of chaperon activity by PRIMA-1MET would lead
to the accumulation of protein aggregates as well as a reac-
tive increase of Hsp70 expression.
Direct interaction with the Hsp70 family of chaperons is
also a common denominator of EBNA-5 and mutant p53.
The Hsp70 family members are also among the most
potent anti-apoptotic agents that can block both the
extrinsic (membrane signalling initiated) and the intrinsic
(mitochondrial cytochrome C release initiated) pro-apop-
totic signal pathways [23].
Transformation of primary B-cells by EBV is dependent on
the EBNA-2 induced activation of numerous viral and cel-
lular genes [3,4,24,25]. EBNA-5 enhances this transactiva-
tion. Hsp70 is a major complexing partner of EBNA-5
[26]. Elevated expression of Hsp70 increases, and sup-
pressed expression of Hsp70 decreases the effect of EBNA-
5 on EBNA-2 mediated transactivation. It has been sug-
gested that Hsp70 chaperon activity may help EBNA-5 in
shuttling off repressors from EBNA2-enhanced promoters
[27].
We have previously shown that inhibition of proteasome
activity leads to synchronous nucleolar translocation of
The PRIMA-1MET-induced nucleolar translocation of DSRed- EBNA-5 is reversible in the p53 -/- H1299 cells Figure 8
The PRIMA-1MET-induced nucleolar translocation of 
DSRed-EBNA-5 is reversible in the p53 -/- H1299 
cells. The translocation was induced by 12 hours drug treat-
ment followed by extensive washing with drug free medium. 
Time-lapse movie was recorded for 6 hours, one frame per 
minute. The fluorescence images are combined with phase 
contrast pictures to demonstrate the intact cellular morphol-
ogy of the cells during the entire length of the experiment.Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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mutant p53, EBNA-5 and Hsp70 in transfected SW480
cells. We have also shown that increased level of EBNA-5
enhanced the nucleolar translocation of mutant p53 [9].
More recently we found that the simultaneous presence of
EBNA-5 and mutant p53 sensitizes cells for MG132 and
bortezomib induced cytotoxicity (R. Ötvös et al, to be
published). These data also suggest there is a close func-
tional interplay between mutant p53 and EBNA-5.
PRIMA-1MET was identified as a low molecular weight
compound that can enhance apoptosis in mutant p53 car-
rying cells, compared to the p53 null parental cells. Most
p53 mutants are in complex with Hsp70 proteins. We
have recently shown that PRIMA-1MET treatment increases
Hsp70 expression and nucleolar translocation, in parallel
with the induction of nucleolar accumulation of mutant
p53 [18]. Numerous experiments indicate that the
increased apoptosis induction is accompanied by the acti-
vation of p53 target genes [28-32]. Several lines of evi-
dence suggest that PRIMA-1MET can also act independently
of the p53 status of the cell. It can radiosensitize prostate
carcinoma cell lines with mutant or wild type p53 and
p53 -/- cells as well [33]. Introduction of mutant p53
(p53ser249 or p53gln248) into p53 -/- hepatocarcinoma
cells increases sensitivity to PRIMA-1MET  without the
induction of p53 target genes [34].
PRIMA-1MET is a powerful apoptosis-inducing agent. Iden-
tification of its targets is partly hindered by the difficulties
to separate its effect from the numerous molecular
changes associated with cellular agony subsequent to drug
treatment. Here we show that subcellular distribution of
EBNA-5 changes in parallel with mutant p53 itself upon
PRIMA-1METtreatment. Similar changes in EBNA5 distri-
bution occur in cells that lack p53 and are therefore resist-
ant for p53 induced apoptosis. We propose that EBNA-5
may serve as a surrogate target that may help to elucidate
the molecular action of PRIMA-1MET.
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Additional material
Additional file 1
Distribution of DSRed-EBNA-5 in the nucleus of MCF7 cell (corre-
sponding to Figure3). In stably transfected cells DSRed-EBNA-5 is dis-
tributed homogeneously in the euchromatin and in well-defined round 
spaces in the zona granulosa of the nucleolus. Importantly the fluorescence 
intensity of the fusion protein is the same in the nucleolar and in the 
nucleoplasmic fraction. Left side – Animation moving through a series of 
21 confocal sections along the Z axis. Rigth side – 3D projection and 
360° rotation of the maximum intensity projected images around the Y 
axis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-23-S1.gif]
Additional file 2
Six minutes time-lapse movie, showing DSRed-EBNA-5 in the nucleus 
of MCF7 cell. Single confocal section with sampling in every 2 seconds 
(122 timepoints). The movie shows that in the nucleoplasm DSRed-
EBNA-5 fills up the space between the bundles of 300 nm chromatin 
fibres. The fiber bundles appear as dark shadows over the uniformly bright 
fluorescence background. The film also shows that the chromatin fibers are 
more densely packed area that corresponds to the fibrillar compartment of 
the nucleolus thus providing the structural basis for the postulated molec-
ular sieve with small pore size.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-23-S2.gif]
Additional file 3
Survival rate of PRIMA-1MET treated MCF7 (wtp53) and SW480 
(mp53) cells in the presence and absence of EBNA-5.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-23-S3.tiff]
Additional file 4
Time-lapse movie of PRIMA-1MET-induced nucleolar accumulation of 
DSRed-EBNA-5 in stably transfected MCF7 cells (corresponding to 
Figure4). The nucleolar accumulation starts non-synchronously in differ-
ent nuclei between 3–9 hours after exposition to the drug.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-23-S4.gif]
Additional file 5
High resolution magnified image of a single nucleus from the movie 
of Additional file3. The movie shows that the accumulation of DSRed-
EBNA-5 is starting non-synchronously in different nucleoli initiating from 
single foci. The movie also illustrates the escape of precipitated DSRed-
EBNA-5 particles from the nucleolus and their travelling through the 
nucleoplasm by random Brownian movement.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-23-S5.gif]Molecular Cancer 2009, 8:23 http://www.molecular-cancer.com/content/8/1/23
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Additional file 7
Time-lapse movie of the FLIP experiment on PRIMA-1MET- treated cell 
shown in Figure7. The movie clearly shows that there is no loss of fluo-
rescence even in the immediate neighbourhood of the bleached area indi-
cating complete immobilisation (precipitation) of DSRed-EBNA-5 upon 
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was illustrated in Additional file 2).
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